Status:
COMPLETED
HDCT and Stem Cell Transplantation for Mantle Cell and Relapsed Low Grade Non-hodgkin's Lymphoma
Lead Sponsor:
Alberta Health services
Conditions:
Low Grade Lymphoma
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation.
Detailed Description
Low grade lymphoma patients receive R-ICE reinduction therapy followed by allogeneic stem cell transplanation if they have an HLA matched sibling, or an autologous transplant if they do not.
Eligibility Criteria
Inclusion
- indolent histology lymphomas after relapse 1 or 2 LVEF \> 50% Creatinine \< 150 umol/L bilirubin \< 30 umol/L wbc \>3.5X10\^9/L platelets \>100X10\^9/L other medical condition as controlled
Exclusion
- pregnant lactating HIV positive CNS involvement by lymphoma other malignancy
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2010
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00144092
Start Date
May 1 2001
End Date
June 1 2010
Last Update
November 21 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2